Maze Therapeutics, Inc.
MAZE · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | |
|---|---|---|---|
| Market Cap | $1 | $1 | $1 |
| - Cash | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 |
| Enterprise Value | $1 | $1 | $1 |
| Revenue | $0 | $0 | $0 |
| % Growth | – | – | – |
| Gross Profit | $0 | $0 | $0 |
| % Margin | 100% | – | – |
| EBITDA | $0 | -$0 | -$0 |
| % Margin | 36.3% | – | – |
| Net Income | $0 | -$0 | -$0 |
| % Margin | 31.2% | – | – |
| EPS Diluted | 0.078 | -2.294 | -2.626 |
| % Growth | 103.4% | 12.6% | – |
| Operating Cash Flow | $0 | -$0 | -$0 |
| Capital Expenditures | -$0 | -$0 | -$0 |
| Free Cash Flow | $0 | -$0 | -$0 |